SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...

China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.

Biotech stocks remain a hot sector for retail traders on Stocktwits, which collectively boast over 3.45 million followers. In ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...

The company on Wednesday announced it paid $47 million up front to license MRG007, a drug developed by Lepu Biopharma, a Shanghai-based developer of cancer therapies. MRG007 is an antibody drug ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in ...

A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

The owner of the Los Angeles Times discusses his fight to cure cancer and why he wants President Donald Trump to succeed in ...

This drug is a small molecule inhibitor of tyrosine kinases, enzymes that drive cancer growth. Tyrosine kinase inhibitors (TKIs) are already available, such as the Novartis drugs Scemblix and Gleevec.

Shares in clinical-stage biotechnology company Cargo Therapeutics (CRGX) have plunged after it scrapped trials of a cancer ...